APA (7th ed.) Citation

Xu, J., Cui, J., Jiang, H., Zeng, Y., & Cong, X. (2023). Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients. Wiley.

Chicago Style (17th ed.) Citation

Xu, Jianming, Jiuwei Cui, Haiping Jiang, Yan Zeng, and Xiuyu Cong. Phase 1 Dose Escalation Study of FGFR4 Inhibitor in Combination with Pembrolizumab in Advanced Solid Tumors Patients. Wiley, 2023.

MLA (9th ed.) Citation

Xu, Jianming, et al. Phase 1 Dose Escalation Study of FGFR4 Inhibitor in Combination with Pembrolizumab in Advanced Solid Tumors Patients. Wiley, 2023.